STLN THE ONCOLOGY INSTITUTE INC revenue, earnings and financials

For the quarter ended June 30, 2026, THE ONCOLOGY INSTITUTE INC reported revenue of $161M (up 34.6% from a year earlier), net income of −$9.79M and diluted EPS of −$0.08; over the last four quarters revenue was $587M and net income $60.6B; for the fiscal year ended December 2025 revenue was $503M, up 27.8% on the year before.

STLN annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $503M, gross profit n/a, operating income −$36.1M, net income $60.6B (margin 12055.4%), EPS −$0.54
• Fiscal year ended Dec 2024: revenue $393M, gross profit n/a, operating income −$60.1M, net income $64.7B (margin 16436.5%), EPS −$0.71
• Fiscal year ended Dec 2023: revenue $324M, gross profit n/a, operating income −$77.0M, net income −$83.1M (margin -25.6%), EPS −$0.92
• Fiscal year ended Dec 2022: revenue $252M, gross profit n/a, operating income −$82.0M, net income $152K (margin 0.1%), EPS −$0.21
• Fiscal year ended Dec 2021: revenue $203M, gross profit n/a, operating income −$45.9M, net income −$10.9M (margin -5.4%), EPS −$0.16

STLN quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $161M (up 34.6% year over year), net income −$9.79M, EPS −$0.08
• Quarter ended Mar 31, 2026: revenue $147M (up 41.2% year over year), net income −$2.49M, EPS −$0.02
• Quarter ended Dec 31, 2025 (from the annual report): revenue $142M (up 41.6% year over year), net income $60.7B, EPS −$0.04
• Quarter ended Sep 30, 2025: revenue $137M (up 36.7% year over year), net income −$16.5M, EPS −$0.14
• Quarter ended Jun 30, 2025: revenue $120M (up 21.5% year over year), net income −$17.0M, EPS −$0.15
• Quarter ended Mar 31, 2025: revenue $104M (up 10.3% year over year), net income −$19.6M, EPS −$0.21
• Quarter ended Dec 31, 2024 (from the annual report): revenue $100M (up 16.9% year over year), net income $64.7B, EPS −$0.14
• Quarter ended Sep 30, 2024: revenue $99.9M (up 21.8% year over year), net income −$16.1M, EPS −$0.18
• Quarter ended Jun 30, 2024: revenue $98.6M (up 22.9% year over year), net income −$15.5M, EPS −$0.17
• Quarter ended Mar 31, 2024: revenue $94.7M (up 24.2% year over year), net income −$19.9M, EPS −$0.22
• Quarter ended Dec 31, 2023 (from the annual report): revenue $85.8M (up 20.1% year over year), net income −$18.8M, EPS −$0.21
• Quarter ended Sep 30, 2023: revenue $82.0M (up 26.3% year over year), net income −$17.4M, EPS −$0.19
• Quarter ended Jun 30, 2023: revenue $80.2M (up 31.7% year over year), net income −$16.9M, EPS −$0.19
• Quarter ended Mar 31, 2023: revenue $76.2M (up 38.1% year over year), net income −$30.0M, EPS −$0.33
• Quarter ended Dec 31, 2022 (from the annual report): revenue $71.4M (up 36.6% year over year), net income −$11.0M, EPS −$0.19
• Quarter ended Sep 30, 2022: revenue $65.0M (up 24.3% year over year), net income −$2.67M, EPS −$0.17
• Quarter ended Jun 30, 2022: revenue $60.9M (up 22.2% year over year), net income −$5.45M, EPS −$0.06
• Quarter ended Mar 31, 2022: revenue $55.2M (up 13.5% year over year), net income $19.3M, EPS $0.21
• Quarter ended Dec 31, 2021 (from the annual report): revenue $52.3M, net income −$10.2M, EPS −$0.14
• Quarter ended Sep 30, 2021: revenue $52.3M, net income −$2.98M, EPS −$0.05

STLN cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$24.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$26.5M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow −$36.3M, share buybacks $1.02M
• Fiscal year ended Dec 2022: operating cash flow −$61.8M, share buybacks $9.00M
• Fiscal year ended Dec 2021: operating cash flow −$32.7M, share buybacks $0

STLN balance sheet

• Jun 30, 2026: cash n/a, total assets $178M, total liabilities $203M, shareholders' equity −$24.9M, long-term debt $79.9M
• Mar 31, 2026: cash n/a, total assets $168M, total liabilities $185M, shareholders' equity −$16.3M, long-term debt $78.6M
• Dec 31, 2025: cash n/a, total assets $165M, total liabilities $180M, shareholders' equity −$15.7M, long-term debt $77.4M
• Sep 30, 2025: cash n/a, total assets $164M, total liabilities $176M, shareholders' equity −$12.3M, long-term debt $76.2M
• Jun 30, 2025: cash n/a, total assets $160M, total liabilities $169M, shareholders' equity −$8.99M, long-term debt $75.0M
• Mar 31, 2025: cash n/a, total assets $164M, total liabilities $159M, shareholders' equity $5.07M, long-term debt $73.9M
• Dec 31, 2024: cash n/a, total assets $173M, total liabilities $169M, shareholders' equity $3.59M, long-term debt $93.1M
• Sep 30, 2024: cash n/a, total assets $179M, total liabilities $164M, shareholders' equity $15.5M, long-term debt $91.5M

What is STLN's revenue?

THE ONCOLOGY INSTITUTE INC reported $587M of revenue over its last four quarters, through June 30, 2026.

Is STLN profitable?

Yes. THE ONCOLOGY INSTITUTE INC earned $60.6B over the last four quarters.

What is STLN's EPS?

Diluted earnings per share over the last four quarters were −$0.28; −$0.08 in the latest quarter.

STLN ownership and insider trades · All stocks